Awardee OrganizationUNIV OF MASSACHUSETTS MED SCH WORCESTER
Description
Abstract Text
DESCRIPTION (provided by applicant): Upon activation by antigen, B cells undergo antibody class (isotype) switching, changing from expression of IgM to expression of IgG, IgA or IgE, while maintaining specificity for the same antigen. Since the isotype determines the effector function of the antibody, class switching allows the humoral immune response to adaptively respond to different infectious organisms. Class switching occurs by a DNA recombination event between switch (S) region sequences located upstream of each heavy chain constant (CH) region gene. This process has mechanistic similarities to somatic hypermutation of Ig variable region genes. It has recently become clear that activation-induced cytidine deaminase (AID) initiates class switch recombination (CSR) by deamination of dC residues within S regions, creating dU residues. The resulting dU residues are excised by uracil DNA glycosylase (UNG) leaving a basic residues, and mice and humans without UNG have greatly reduced abilities to undergo CSR. However, in order to initiate CSR, the abasic site must be converted to a single strand DNA break. This has been hypothesized to be due to AP endonuclease (APE) but which of the two APEs might be involved are unknown. Another possibility is supported by data from this group, suggesting that the endonuclease ERCC1/XPF might also have this role. One of the goals of this grant is to determine how the initiating DNA breaks are introduced. A related goal is to determine the mechanisms for introduction of mutations into S regions during the DNA repair processes accompanying CSR. There are 4 specific aims directed towards these goals. Aim 1: to determine if components of the nucleotide excision repair (NER) pathway, in addition to ERCC1/XPF, are involved in CSR and to determine their role. Aim 2: to determine if the base excision repair (BER) enzymes APE1 or APE2 create the initiating DNA breaks in the Su segments. Aim 3: to determine if the BER and NER pathways are redundant for creation of the initiating DNA breaks and if there is a competition between these pathways. We will also explore if the competition is altered by activation of B cells in the presence of different induction conditions. In Aim 4 we will explore how the mutations are introduced into Ig S regions by determining if the translesion DNA polymerase iota is involved in the error-prone repair of S regions and if this involvement is regulated by cytokines.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
APEXL2 GeneAntibodiesAntigensB-Cell ActivationBase Excision RepairsCD80 AntigensClassConditionDNADNA Polymerase IDNA RepairDNA Single Strand BreakDNA polymerase iotaDNA-(apurinic or apyrimidinic site) lyaseDNA-Directed DNA PolymeraseDataDeaminationERCC1 geneEnzymesEventExcisionGenesGenetic RecombinationGoalsGrantHumanIgEImmune responseImmunoglobulin AImmunoglobulin Class SwitchingImmunoglobulin GImmunoglobulin MImmunoglobulin Somatic HypermutationImmunoglobulin Switch RecombinationInfectious AgentLeftLesionMusMutationNucleotide Excision RepairPathway interactionsPolymeraseProcessRegulationRoleSiteSpecificityStructureXPA geneactivation-induced cytidine deaminasebaseconstant region genecytokineendonucleasehuman APEX1 proteinprotein expressionrepair enzymerepaireduracil-DNA glycosylasevariable region gene
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
603847393
UEI
MQE2JHHJW9Q8
Project Start Date
01-February-2005
Project End Date
31-January-2009
Budget Start Date
01-February-2007
Budget End Date
31-January-2009
Project Funding Information for 2007
Total Funding
$308,159
Direct Costs
$189,636
Indirect Costs
$118,523
Year
Funding IC
FY Total Cost by IC
2007
National Institute of Allergy and Infectious Diseases
$308,159
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI063026-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI063026-03
Patents
No Patents information available for 5R01AI063026-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI063026-03
Clinical Studies
No Clinical Studies information available for 5R01AI063026-03
News and More
Related News Releases
No news release information available for 5R01AI063026-03
History
No Historical information available for 5R01AI063026-03
Similar Projects
No Similar Projects information available for 5R01AI063026-03